Table 2 Clinical data on DEB-TACE

Microsphere of 100–300/300-500 μm

6 (12.2%)/43 (87.8%)

Polyvinyl alcohol particles

6 (12.2%)

Gelatin sponge particles

11 (22.4%)

Embolization microspheres

2 (4.1%)

Median inpatient duration, months

10.0 (7.0, 13.0)

Total cost of hospitalization, × 10⁴￥

7.1 (5.3, 10.8)

Mean session of DEB-TACE

1.7 ± 1.2

Complications, n (%)

17 (58.6%)

Fever

4 (13.8%)

 Nausea and/or vomiting

5 (17.2%)

 Abdominal pain

12 (41.4%)

 Raised ALT/AST

8 (27.6%)

 Hematoma

1 (3.4%)

Other related treatments, n (%)

19 (65.5%)

 cTACE

9 (31.0%)

 Portal vein stenting

1 (3.4%)

 ¹²⁵I seeds implantation

4 (13.8%)

 Thermal ablation

9 (31.0%)